We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.
- Authors
Bushe, Chris J; Slooff, Cees J; Haddad, Peter M; Karagianis, Jamie L
- Abstract
The aim was to explore weight and body mass index (BMI) changes by baseline BMI in patients completing three years of monotherapy with various first- and second-generation antipsychotics in a large cohort in a post hoc analysis of three-year observational data.Data were analyzed by antipsychotic and three baseline BMI bands: underweight/normal weight (BMI <25 kg/m2), overweight (25–30 kg/m2) and obese (>30 kg/m2).Baseline BMI was associated with subsequent weight change irrespective of the antipsychotic given. Specifically, a smaller proportion of patients gained ≥7% baseline bodyweight, and a greater proportion of patients lost ≥7% baseline bodyweight with increasing baseline BMI. For olanzapine (the antipsychotic associated with highest mean weight gain in the total drug cohort), the percentage of patients gaining ≥7% baseline weight was 45% (95% CI: 43–48) in the underweight/normal weight BMI cohort and 20% (95% CI: 15–27) in the obese BMI cohort; 7% (95% CI: 6–8) of the underweight/normal cohort and 19% (95% CI: 13–27) of the obese cohort lost ≥7% baseline weight.BMI has an association with the likelihood of weight gain or loss and should be considered in analyses of antipsychotic weight change.
- Subjects
BODY mass index; ANTHROPOMETRY; ANTIPSYCHOTIC agents; PSYCHIATRIC drugs; PHYSICAL anthropology
- Publication
Journal of Psychopharmacology, 2013, Vol 27, Issue 4, p358
- ISSN
0269-8811
- Publication type
Article
- DOI
10.1177/0269881112473789